Great Novel Therapeutics Biotech & Medicals (TPEX:7427)
Taiwan · Delayed Price · Currency is TWD 73.50
+0.10 (0.14%)
Sep 8, 2026, 1:48 PM CST
TPEX:7427 Revenue
Great Novel Therapeutics Biotech & Medicals had revenue of 5.63M TWD in the half year ending June 30, 2026, with 967.55% growth. This brings the company's revenue in the last twelve months to 6.21M, up 248.57% year-over-year. In the year 2025, Great Novel Therapeutics Biotech & Medicals had annual revenue of 1.21M, down -28.49%.
Revenue (ttm)
6.21M
Revenue Growth
+248.57%
P/S Ratio
625.64
Revenue / Employee
269.91K
Employees
22
Market Cap
3.88B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.21M | -480.00K | -28.49% |
| Dec 31, 2024 | 1.69M | -3.17M | -65.26% |
| Dec 31, 2023 | 4.85M | 4.31M | 798.15% |
| Dec 31, 2022 | 540.00K | -90.00K | -14.29% |
| Dec 31, 2021 | 630.00K | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Apex Biotechnology | 1.87B |
| SYN-TECH Chem. & Pharm. | 1.27B |
| Chunghwa Chemical Synthesis & Biotech | 934.29M |
| Sagittarius Life Science | 467.69M |
| BioGend Therapeutics | 236.58M |
| OBI Pharma | 52.20M |
| Shine-On BioMedical | 50.62M |
| Intech Biopharm | 48.55M |